TargetingMETDysregulation in Cancer
| Autor: | Mark M. Awad, Gonzalo Recondo, Pasi A. Jänne, Jianwei Che |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Mutation MET Gene Amplification business.industry Cancer Drug resistance medicine.disease medicine.disease_cause 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer research Medicine Biomarker discovery business Carcinogenesis |
| Zdroj: | Cancer Discovery. 10:922-934 |
| ISSN: | 2159-8290 2159-8274 |
| Popis: | Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of molecular mechanisms including MET gene amplification, mutation, rearrangement, and overexpression. Improvements in biomarker discovery and testing have more recently enabled the selection of patients with MET-dependent cancers for treatment with potent, specific, and novel MET-targeting therapies. We review the known oncologic processes that activate MET, discuss therapeutic strategies for MET-dependent malignancies, and highlight emerging challenges in acquired drug resistance in these cancers.Significance:Increasing evidence supports the use of MET-targeting therapies in biomarker-selected cancers that harbor molecular alterations in MET. Diverse mechanisms of resistance to MET inhibitors will require the development of novel strategies to delay and overcome drug resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|